or some opioid makers, the financial outlook is painful.

Between falling prices for many of the medicines and fast-growing litigation, a few of these companies have only modest flexibility to cope with these mounting risks, according to a new analysis by Moody’s Investor Service. And the drug maker most likely to be impacted is Endo International (ENDP).

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

    • Hi Gaurav,
      The report is called ‘Drug manufacturers and distributors face rising risks related to the US opioid crisis’ and was released on Nov. 30.
      ed at Pharmalot

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.